338 related articles for article (PubMed ID: 26370671)
1. Gene expression of thyroid-specific transcription factors may help diagnose thyroid lesions but are not determinants of tumor progression.
Batista FA; Ward LS; Marcello MA; Martins MB; Peres KC; Torricelli C; Bufalo NE; Soares FA; da Silva MJ; Assumpção LV
J Endocrinol Invest; 2016 Apr; 39(4):423-9. PubMed ID: 26370671
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.
Kebebew E; Peng M; Reiff E; Duh QY; Clark OH; McMillan A
Surgery; 2005 Dec; 138(6):1102-9; discussion 1109-10. PubMed ID: 16360397
[TBL] [Abstract][Full Text] [Related]
3. PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues.
Lacroix L; Mian C; Barrier T; Talbot M; Caillou B; Schlumberger M; Bidart JM
Eur J Endocrinol; 2004 Sep; 151(3):367-74. PubMed ID: 15362967
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms.
Nonaka D; Tang Y; Chiriboga L; Rivera M; Ghossein R
Mod Pathol; 2008 Feb; 21(2):192-200. PubMed ID: 18084247
[TBL] [Abstract][Full Text] [Related]
5. Muc-1 expression may help characterize thyroid nodules but does not predict patients' outcome.
Morari EC; Silva JR; Guilhen AC; Cunha LL; Marcello MA; Soares FA; Vassallo J; Ward LS
Endocr Pathol; 2010 Dec; 21(4):242-9. PubMed ID: 21057891
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of DREAM gene mRNA levels in thyroid tumours.
Batista FA; Marcello MA; Martins MB; Peres KC; Cardoso UO; Silva ACDN; Bufalo NE; Soares FA; Silva MJD; Assumpção LV; Ward LS
Arch Endocrinol Metab; 2018; 62(2):205-211. PubMed ID: 29641740
[TBL] [Abstract][Full Text] [Related]
7. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
8. PAX8/PPARγ rearrangement in thyroid nodules predicts follicular-pattern carcinomas, in particular the encapsulated follicular variant of papillary carcinoma.
Armstrong MJ; Yang H; Yip L; Ohori NP; McCoy KL; Stang MT; Hodak SP; Nikiforova MN; Carty SE; Nikiforov YE
Thyroid; 2014 Sep; 24(9):1369-74. PubMed ID: 24798894
[TBL] [Abstract][Full Text] [Related]
9. An antibody-like peptide that recognizes malignancy among thyroid nodules.
Reis CF; Carneiro AP; Vieira CU; Fujimura PT; Morari EC; Silva SJ; Goulart LR; Ward LS
Cancer Lett; 2013 Jul; 335(2):306-13. PubMed ID: 23462224
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules.
Finley DJ; Arora N; Zhu B; Gallagher L; Fahey TJ
J Clin Endocrinol Metab; 2004 Jul; 89(7):3214-23. PubMed ID: 15240595
[TBL] [Abstract][Full Text] [Related]
11. Methylation markers differentiate thyroid cancer from benign nodules.
Stephen JK; Chen KM; Merritt J; Chitale D; Divine G; Worsham MJ
J Endocrinol Invest; 2018 Feb; 41(2):163-170. PubMed ID: 28612287
[TBL] [Abstract][Full Text] [Related]
12. PREDICTIVE VALUE OF SOMATIC MUTATIONS FOR THE DEVELOPMENT OF MALIGNANCY IN THYROID NODULES BY CYTOPATHOLOGY.
Halászlaki C; Tóbiás B; Balla B; Kósa JP; Horányi J; Bölöny E; Nagy Z; Speer G; Járay B; Székely E; Istók R; Székely T; Putz Z; Dank M; Lakatos P; Takács I
Endocr Pract; 2016 Sep; 22(9):1081-7. PubMed ID: 27214302
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
14. Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis.
Borrelli N; Ugolini C; Giannini R; Antonelli A; Giordano M; Sensi E; Torregrossa L; Fallahi P; Miccoli P; Basolo F
Cancer Cytopathol; 2016 May; 124(5):340-9. PubMed ID: 26749005
[TBL] [Abstract][Full Text] [Related]
15. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
16. [Nodule diagnosed as follicular patterned lesion: are biomarkers the promise?].
Cerutti JM
Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):832-42. PubMed ID: 17891248
[TBL] [Abstract][Full Text] [Related]
17. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
Jug RC; Datto MB; Jiang XS
Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
[TBL] [Abstract][Full Text] [Related]
18. In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications.
Guo Z; Hardin H; Montemayor-Garcia C; Asioli S; Righi A; Maletta F; Sapino A; Lloyd RV
Endocr Pathol; 2015 May; 26(2):157-63. PubMed ID: 25771986
[TBL] [Abstract][Full Text] [Related]
19. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
20. TROP-2 expression in papillary thyroid carcinoma: Potential Diagnostic Utility.
Simms A; Jacob RP; Cohen C; Siddiqui MT
Diagn Cytopathol; 2016 Jan; 44(1):26-31. PubMed ID: 26481593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
